Stay updated with breaking news from Antonio passaro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Compared to chemotherapy alone, amivantamab plus chemotherapy treatment with and without lazertinib had also demonstrated positive trends in OS and ORR in patients with NSCLC. ....
Data from three trials with the amivantamab in advanced EGFR-mutant NSCLC have yielded "exciting" results with experts hailing the drug as standard of care in various settings. ....
MARIPOSA demonstrated the combination reduced risk of progression or death by 30% compared with osimertinib. MARIPOSA-2 found amivantamab plus chemotherapy and amivantamab plus chemotherapy and lazertinib also improved progression-free survival (PFS) over chemotherapy after progression on osimertinib. ....
Patients with EGFR-mutated advanced non–small cell lung cancer who experienced disease progression after treatment with osimertinib experienced a progression-free survival benefit with amivantamab plus chemotherapy with or without lazertinib compared with chemotherapy alone. ....
<p><em>Lugano, Switzerland, 17 October 2023</em> – More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumour cells, with less need for chemotherapy, following results of multiple landmark clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023.</p> ....